These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 35815386)

  • 1. The association between buprenorphine treatment duration and mortality: a multi-site cohort study of people who discontinued treatment.
    Glanz JM; Binswanger IA; Clarke CL; Nguyen AP; Ford MA; Ray GT; Xu S; Hechter RC; Yarborough BJH; Roblin DW; Ahmedani B; Boscarino JA; Andrade SE; Rosa CL; Campbell CI
    Addiction; 2023 Jan; 118(1):97-107. PubMed ID: 35815386
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prescribing Characteristics Associated With Opioid Overdose Following Buprenorphine Taper.
    Bozinoff N; Men S; Kurdyak P; Selby P; Gomes T
    JAMA Netw Open; 2022 Sep; 5(9):e2234168. PubMed ID: 36173629
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Duration of use and outcomes among people with opioid use disorder initiating methadone and buprenorphine in Ontario: a population-based propensity-score matched cohort study.
    Gomes T; McCormack D; Bozinoff N; Tadrous M; Antoniou T; Munro C; Campbell T; Paterson JM; Mamdani M; Sproule B
    Addiction; 2022 Jul; 117(7):1972-1981. PubMed ID: 35257434
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Opioid agonist treatment and fatal overdose risk in a state-wide US population receiving opioid use disorder services.
    Krawczyk N; Mojtabai R; Stuart EA; Fingerhood M; Agus D; Lyons BC; Weiner JP; Saloner B
    Addiction; 2020 Sep; 115(9):1683-1694. PubMed ID: 32096302
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Associations between prescribed benzodiazepines, overdose death and buprenorphine discontinuation among people receiving buprenorphine.
    Park TW; Larochelle MR; Saitz R; Wang N; Bernson D; Walley AY
    Addiction; 2020 May; 115(5):924-932. PubMed ID: 31916306
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Does opioid agonist treatment reduce overdose mortality risk in people who are older or have physical comorbidities? Cohort study using linked administrative health data in New South Wales, Australia, 2002-17.
    Larney S; Jones NR; Hickman M; Nielsen S; Ali R; Degenhardt L
    Addiction; 2023 Aug; 118(8):1527-1539. PubMed ID: 36843415
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Duration of medication treatment for opioid-use disorder and risk of overdose among Medicaid enrollees in 11 states: a retrospective cohort study.
    Burns M; Tang L; Chang CH; Kim JY; Ahrens K; Allen L; Cunningham P; Gordon AJ; Jarlenski MP; Lanier P; Mauk R; McDuffie MJ; Mohamoud S; Talbert J; Zivin K; Donohue J
    Addiction; 2022 Dec; 117(12):3079-3088. PubMed ID: 35652681
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Modeling the cost-effectiveness and impact on fatal overdose and initiation of buprenorphine-naloxone treatment at syringe service programs.
    Adams JW; Savinkina A; Fox A; Behrends CN; Madushani RWMA; Wang J; Chatterjee A; Walley AY; Barocas JA; Linas BP
    Addiction; 2022 Oct; 117(10):2635-2648. PubMed ID: 35315148
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association between jail-based methadone or buprenorphine treatment for opioid use disorder and overdose mortality after release from New York City jails 2011-17.
    Lim S; Cherian T; Katyal M; Goldfeld KS; McDonald R; Wiewel E; Khan M; Krawczyk N; Braunstein S; Murphy SM; Jalali A; Jeng PJ; MacDonald R; Lee JD
    Addiction; 2023 Mar; 118(3):459-467. PubMed ID: 36305669
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Buprenorphine Treatment Intake and Critical Encounters following a Nonfatal Opioid Overdose.
    Victor GA; Bailey K; Ray B
    Subst Use Misuse; 2021; 56(7):988-996. PubMed ID: 33749520
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Medication for Opioid Use Disorder After Nonfatal Opioid Overdose and Association With Mortality: A Cohort Study.
    Larochelle MR; Bernson D; Land T; Stopka TJ; Wang N; Xuan Z; Bagley SM; Liebschutz JM; Walley AY
    Ann Intern Med; 2018 Aug; 169(3):137-145. PubMed ID: 29913516
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Acute Care, Prescription Opioid Use, and Overdose Following Discontinuation of Long-Term Buprenorphine Treatment for Opioid Use Disorder.
    Williams AR; Samples H; Crystal S; Olfson M
    Am J Psychiatry; 2020 Feb; 177(2):117-124. PubMed ID: 31786933
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Buprenorphine After Nonfatal Opioid Overdose: Reduced Mortality Risk in Medicare Disability Beneficiaries.
    Samples H; Nowels MA; Williams AR; Olfson M; Crystal S
    Am J Prev Med; 2023 Jul; 65(1):19-29. PubMed ID: 36906496
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fatal and non-fatal opioid overdose in opioid dependent patients treated with methadone, buprenorphine or implant naltrexone.
    Kelty E; Hulse G
    Int J Drug Policy; 2017 Aug; 46():54-60. PubMed ID: 28609749
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Baseline Factors Associated with Mortality in Patients Who Engaged in Buprenorphine Treatment for Opioid Use Disorder: a Cohort Study.
    Fine DR; Yu L; Triant VA; Baggett TP; Metlay JP
    J Gen Intern Med; 2020 Aug; 35(8):2375-2382. PubMed ID: 32206993
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association Between Buprenorphine for Opioid Use Disorder and Mortality Risk.
    Vakkalanka P; Lund BC; Arndt S; Field W; Charlton M; Ward MM; Carnahan RM
    Am J Prev Med; 2021 Sep; 61(3):418-427. PubMed ID: 34023160
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Higher First 30-Day Dose of Buprenorphine for Opioid Use Disorder Treatment Is Associated With Decreased Mortality.
    Lei F; Lofwall MR; McAninch J; Adatorwovor R; Slade E; Freeman PR; Moga DC; Dasgupta N; Walsh SL; Vickers-Smith R; Slavova S
    J Addict Med; 2024 May-Jun 01; 18(3):319-326. PubMed ID: 38598300
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Examining buprenorphine diversion through a harm reduction lens: an agent-based modeling study.
    Adams JW; Duprey M; Khan S; Cance J; Rice DP; Bobashev G
    Harm Reduct J; 2023 Oct; 20(1):150. PubMed ID: 37848945
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mortality risk of opioid substitution therapy with methadone versus buprenorphine: a retrospective cohort study.
    Kimber J; Larney S; Hickman M; Randall D; Degenhardt L
    Lancet Psychiatry; 2015 Oct; 2(10):901-8. PubMed ID: 26384619
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Psychosocial and behavioral therapy in conjunction with medication for opioid use disorder: Patterns, predictors, and association with buprenorphine treatment outcomes.
    Samples H; Williams AR; Crystal S; Olfson M
    J Subst Abuse Treat; 2022 Aug; 139():108774. PubMed ID: 35337716
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.